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Dear Editor, 
We read with interest and concern two reports published in HUMAN PATHOLOGY [1,2] 
concerning testicular neoplasms that were felt to be “testicular analogues” of the well-known 
“solid pseudopapillary neoplasm” (SPN) of the pancreas, albeit in one of the 2 papers the authors 
preferred to designate the tumors as primary signet ring stromal tumors of the testis [1]. 
Although we acknowledge that the pseudopapillae in the SPNs may be limited in amount, their 
apparent absence, according to the descriptions of the microscopic findings in all of the 14 
tumors in these 2 reports, struck us as unusual for a tumor the authors were placing in the SPN 
category.  
The 14 tumors had foci of signet ring–type cells as well as solid, nested and trabecular 
patterns of growth. They shared many immunohistochemical reactivities with SPNs, including 
nuclear β-catenin, CD10, CD56 and α-1-antitrypsin in the subset of cases studied by this method. 
The authors reported they were negative for inhibin (0/12) and calretinin (0/12). Eleven 
analyzable tumors had exon 3 mutations in the CTTNB1 gene that encodes β-catenin. In our 
estimation, these tumors fall within the Sertoli cell tumor, not otherwise specified (NOS) 
category of testicular tumors and should not be regarded as SPNs. 
Signet ring–type cells are a well-recognized feature of Sertoli cell tumor, NOS. They 
have previously been illustrated in Sertoli cell tumors by authorities in testicular pathology [3-7] 
(see p. 119, Fig. 5.18 [3]; p. 367, Figure 5.39D [4]; p. 248, fig. 6-20 [5]; p. 790, Fig. 12-79 and p. 
791, Fig. 12-83 [6]; p. 716, Fig. 14 [7]), and they are almost certainly due to large fat vacuoles in 
the cytoplasm. One of us co-authored a large study indicating so, and in that series they were 
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seen in 26 of 60 cases (43%) [7]. The reactivity of Sertoli cell tumor, NOS for a variety of 
antigens, including nuclear β-catenin [8-10] and CD56 [11] is well established, as is their 
variable positivity for inhibin and calretinin. In 5 series, the rate of inhibin reactivity in Sertoli 
cell tumors varied from 25% to 90% [12-16], and a recent study showed calretinin reactivity in 
43% [16]. Negative staining for inhibin and calretinin, therefore, does not exclude Sertoli cell 
tumor. We are not aware of studies that have looked for CD10 or α-1-antitrypsin reactivity in 
testicular Sertoli cell tumors, but ovarian ones are frequently CD10 positive [17]. Additionally 
Sertoli cell tumors, NOS harbor the same exon 3 mutations in the CTTNB1 gene [9,18] as 
described in the testicular tumors considered SPN analogues [1,2]. Our conclusion from these 
data is that there is long-established overlap in many of the immunohistochemical reactivities 
and molecular genetic features of testicular Sertoli cell tumors and pancreatic SPNs. 
We wish to illustrate 2 recent cases of Sertoli cell tumor that we readily found in our files 
that showed similar morphological features to those the authors illustrated and that exhibited 
strong nuclear reactivity for β-catenin (known to correlate with the CTNNB1 mutation [9]) as 
well as significant reactivity for both inhibin and calretinin (Figs. 1 and 2). They presented as 
testicular masses in 43-year-old and 23-year-old men who had negative serum marker studies. In 
the first case, there was significant hollow tubular/glandular differentiation, a feature that is not 
seen in SPNs, although this case also showed the nested, trabecular and solid foci the authors 
emphasized in their descriptions of “SPN analogues.” This tumor showed patchy inhibin and 
calretinin reactivity and diffuse nuclear and cytoplasmic positivity for β-catenin. The second case 
had solid, nested and trabecular patterns with foci of vacuolated tumors cells (?signet ring cells) 
and displayed significant nuclear pleomorphism; it prominently invaded paratesticular blood 
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vessels. It had diffuse inhibin and β-catenin reactivity (calretinin was not performed). It was 
classified as a malignant Sertoli cell tumor, NOS.  
In our opinion, these cases illustrate that Sertoli cell tumors of the testis have overlapping 
features with those of SPN. They additionally share a mutation of a gene that is altered in a 
variety of tumors other that Sertoli cell tumor and SPN, illustrating what is becoming 
increasingly evident concerning the nonspecificity of many molecular genetic changes in tumors. 
We think it is a mistake to equate such tumors with the solid pseudopapillary tumor of the 
pancreas, which has a mostly indolent behavior, because it may well lead to undertreatment 
when, in fact, early aggressive surgical management with retroperitoneal lymph node dissection 
may be life-saving. Our second case is a prime example of an aggressive Sertoli cell tumor that 
should not be regarded as a SPN.  
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Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 
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Figure Legends 
Fig. 1 Sertoli cell tumor from a 43-year-old man shows (A) solid and trabecular growth with 
irregular spaces, (B) prominent hollow tubules, (C) patchy inhibin (left) and calretinin (right) 
positivity, and (D) strong, diffuse nuclear and cytoplasmic reactivity for β-catenin.  
 
Fig. 2 Sertoli cell tumor from a 23-year-old man shows (A) anastomosing solid nests, (B) 
prominent nuclear pleomorphism with intranuclear cytoplasmic inclusions and vacuolated 
cytoplasm, (C) conspicuous large vessel invasion in the paratestis, and (D) strong, diffuse 
cytoplasmic reactivity for inhibin (left) and nuclear and cytoplasmic reactivity for β-catenin 
(right). 
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